Materials & Resources » Chemicals | Hubei Biocause Pharmaceutical Co. Ltd.

Hubei Biocause Pharmaceutical Co. Ltd. A | Ownership

Companies that own Hubei Biocause Pharmaceutical Co. Ltd. A

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
The Vanguard Group, Inc.
3,939,900
0.28%
56,700
0%
07/31/2018
China Asset Management Co., Ltd.
3,740,264
0.28%
451,900
0.02%
12/31/2017
Huatai-PineBridge Fund Management Co., Ltd.
2,486,900
0.18%
162,700
0.05%
12/31/2017
Harvest Fund Management Co., Ltd.
2,327,200
0.17%
153,300
0.02%
07/27/2018
Founder Fubon Fund Management Co. Ltd.
1,613,870
0.12%
1,550,870
0.28%
12/31/2017
Chang Xin Asset Management Co., Ltd.
1,351,800
0.1%
1,351,800
0.05%
12/31/2017
Penghua Fund Management Co., Ltd.
1,259,200
0.09%
-210,300
0.01%
12/31/2017
Orient Fund Management Co., Ltd.
1,026,000
0.08%
997,500
0.16%
12/31/2017
GF Fund Management Co., Ltd.
774,866
0.06%
-138,199
0.01%
12/31/2017
Harvest Global Investments Ltd.
741,700
0.06%
0
0.04%
09/05/2018

About Hubei Biocause Pharmaceutical Co.

View Profile
Address
No. 132 Yangwan Road
Jingmen Hubei 448000
China
Employees -
Website http://www.biocause.com
Updated 07/08/2019
Hubei Biocause Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of chemical products and medicinal raw materials. Its products include homatropine hydrobromide, thiotriazoline, lercanidipine hydrochloride, barnidipine hydrochloride, mitoxantrone hydrochloride, hyoscyamine sulfate, balsalazide sodium, oxaprozin, homatropine methyl bromide, flumazenil, milrinone, granisetron hydrochloride and others. The company was founded on November 18, 1993 and is headquartered in Jingmen, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.